UW Medicine provides a full spectrum of cancer management – from prevention to caring for newly diagnosed patients, to coordinating specialty care for patients with advanced forms of the disease. We provide leading-edge treatments and clinical trials for brain, breast, colorectal, genitourinary, gynecologic, liver, lung, pancreatic, prostate, skin and sarcoma cancers in addition to lymphatic and other blood cancers.
Cameron J. Turtle, MD, covers the background and rationale for CD19 CAR-T cell therapy, clinical responses and approaches to mitigate toxicity.
Ryan Lynch, MD, on diffuse large B-cell lymphoma and follicular lymphoma: integrating components of IPI score with pathology information to create an evidence-based treatment approach and assessing which patients require systemic and/or local therapy.
Nicole Zern, MD discusses papillary thyroid carcinoma.
Teresa Kim, MD, describes integrating surgery into the multimodal management of soft tissue sarcoma
Ramesh Rengan, MD, discusses the strengths and limitations of proton beam radiotherapy.
Mara Roth, MD, discusses changes in the approach to treatment and management of thyroid cancer.
Raymond Yeung, MD, gives a lecture on minimally invasive therapies for colorectal carcinoma.
Richard Cheng, MD, gives an overview of the risk of cardiovascular complications in cancer survivors.
Mukta Krane, MD, discusses diagnostic and treatment approaches of colorectal cancer.
Douglas Wood, MD, and David Madtes, MD, give a presentation on lung cancer screening and some of the guidelines and development of policy.
Jeffrey Houlton, MD, gives a presentation on HPV and Oropharyngeal cancer.
Kathryn Pennington, MD, describes the patterns of care in treating ovarian cancer, while identifying women who are at risk.
Information & Resources
John D. Scott, MD, spotlights on treating young adults with fibrolamellar carcinoma or FLC.
Colin Pritchard, MD, argues that people of all sexes can have risk genes that are often assumed to affect only women. Renaming the syndrome should aid cancer prevention and treatment.
Brian Shirts, MD, discusses why patients with pathogenic variants in CDH1 should think differently about risk when considering prophylactic gastrectomy.
A new scientific analysis of nearly 4,000 mutations deliberately engineered into the BRCA1 gene will immediately benefit people undergoing genetic testing for breast or ovarian cancer risk.
The first study of its kind applying modern genomics technology to DNA contributed by Sub-Saharan African women has shown they are more likely than women of other ancestries to develop and to die from triple-negative breast cancer. In ...
KING-TV 5 interviews Dr. Rachel Winer, an HPV expert at UW, about new research.
Researchers may have finally found a way to destroy only tumor cells but not surrounding healthy cells.
Research & Publications